. Illustrative is the barrier against access to essential medicines caused by pharmaceutical patent protection under the WTO regime …

action that evaluates patent validity. An economic incentive to challenge weak patents should also be introduced in Canada …

Patent protection for sev ... …

We explore how the Patent Office may improve the quality of issued patents on “secondary” drug features by giving … examiners more time to review drug-patent applications. Our findings suggest that current time allocations are causing examiners … to issue low quality secondary patents on the margin. To assess the merits of expanding ex ante scrutiny of drug-patent …

other types of mechanisms in regulatory laws that provide patent-like protection or further strengthen existing patent … drug companies: data exclusivity and patent linkage. As noted in earlier chapters (separately posted on SSRN), not all … competition, a thorough understanding of these requirements (as well as how they intersect with patent protection) is important to …

associated with Food and Drug Administration (FDA)-mandated clinical trials of new drugs. But the relationship between the patent … system and other regulation of drugs is more complex than this simple formulation suggests. Drug regulation operates in …

Over the past decade, drug makers have settled patent litigation by making large payments to potential rivals who, in …